In episode seventeen, PeDRA Pub Club host Hannah Chang and guest panelists, Bella Plumptre, MD, and Cheryl Bayart, MD, discuss a recent PeDRA publication, Dermatologic Conditions in Down Syndrome: A Multi-Site Retrospective Review of International Classification of Diseases published in Pediatric Dermatology in 2024.

PeDRA Awards Program

PeDRA Annual Conference

Following the June 23 OX40 webinar, Dr. Eichenfield, Dr. Simpson, and Dr. Wan continue the conversation with a look ahead at the future of OX40 therapies and their potential to change the course of disease. They also unpack the complex concept of remission in atopic dermatitis—what it means, how it's defined, and whether it's truly achievable.

To watch the OX40 webinar, please click here.

Disclosures:

Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.

Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX Therapeutics

Eric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkin

Joy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

This engaging and informative webinar explores the role of OX40 and OX40L in pediatric dermatology. OX40: Innovative Insights and Therapeutic Potential in Pediatric Dermatology brings together experts in the field to discuss emerging research, mechanisms of action, and the implications of targeting the OX40 pathway for treating chronic inflammatory skin diseases in children. To view the video version of this webinar, please click here.

Disclosures:

Lawrence Eichenfield, MD has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB.

Eric Simpson, MD reports personal fees from AbbVie, Aclaris Therapeutics, Amgen, Arcutis, Astria Therapeutics, Attovia Therapeutics, Inc., Bambusa Therapeutics Inc., Castle, CorEvitas, Dermira, Eli Lilly, Evomunne, FIDE, Impetus Healthcare, Incyte, Innovaderm Reche/ Indero, Inmagene Biopharmaceuticals, Janssen, LectureLinx (LLX), Leo, NUMAB Therapeutics AG, Pfizer, Recludix Pharma, Regeneron, Roche Products Ltd, Sanofi-Genzyme, SITRYX Therapeutics

Eric Simpson, MD reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, Dermavant, CorEvitas, Dermira, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, Target, VeriSkin

Joy Wan, MD Sun Pharmaceuticals - consulting (DMC), Astria Therapeutics - consulting (ad board), Galderma - fellowship funding (paid to Johns Hopkins)

In this episode of PeDRA Pearls, we host a powerful conversation featuring the Gorlin Syndrome Alliance (GSA). Join us as we delve into the world of Gorlin Syndrome through the heartfelt narrative of Taylor Hodge, who recounts her family's journey following her son's diagnosis at just 18 months old. Joined by Dr. Elena Hawryluk of Harvard Medical School, the discussion sheds light on current research gaps and future directions in the field. Meredith Weiss, Executive Director of the GSA, also contributes, highlighting the essential patient support programs offered by the GSA and the organization's unwavering commitment to research and collaboration. This episode offers a blend of personal insight and professional expertise, providing listeners with a comprehensive understanding of Gorlin Syndrome and the ongoing collaborative efforts to support those affected.

• Subscribe for weekly content!
• Register for OX40
• Pub Club 16
• Molluscum Minute
• PeDRA Annual Conference - Deadlines and Registration
• Funding Opportunities
• Upcoming Conferences and Events
• PeDRA Awards Program

In episode sixteen, Hannah Chang is joined by Dr. Bella Plumptre and Dr. Cheryl Bayart to discuss the article Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas published in JAMA Dermatology in 2025.

• OX40 Webinar Studio Audience
• NextGen Research Forum Information

Join PeDRA Executive Director Mike Siegel, PhD, and Pediatric Dermatologist Dr. Carrie Coughlin, Chair of PeDRA’s Outcomes Committee, as they wrap up our coverage of the Society for Investigative Dermatology (SID) meeting. In this final recap, they highlight key moments from the PeDRA session and discuss why SID is a vital event for anyone involved in pediatric dermatology research. Tune in for insights, takeaways, and a look ahead!

• PeDRA Grants
• PeDRA Annual Conference
• PeDRA Awards
• SPD Annual Meeting
• PHACE Syndrome Conference
• Gorlin Syndrome Alliance Conference
• NAAF Conference
• Eczema Expo